Investigating the role of amylin in diabetic nerve damage
Official title: A Causative Role for Amylin in Diabetic Peripheral Neuropathy
Run by University of Kentucky · NCT03481283 · Data updated 2026-11-12
This study is trying to see if the levels of a hormone called amylin are linked to nerve damage in people with Type-2 diabetes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | University of Kentucky Academic / other |
| Locations | 2 sites (Lexington, Kentucky and 1 other locations) |
| Status | Recruiting |
| Started | February 5, 2018 |
| Main results expected | January 2029 |
| Study ends | January 2029 |
| Registry record updated | January 30, 2026 |
| Trial ID | NCT03481283 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals diagnosed with Type-2 diabetes who exhibit mild-to-severe peripheral neuropathy.
✕Probably not a fit
Patients who do not have a diagnosis of Type-2 diabetes or show normal nerve conduction velocity may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the relationship between amylin levels and the severity of peripheral neuropathy in individuals with Type-2 diabetes. Researchers will collect blood and skin biopsy samples from participants to analyze amylin presence in the upper extremities. Additionally, patient responses to sensory stimuli such as heat, cold, and pressure will be measured to assess neuropathy symptoms. The study seeks to clarify the potential role of amylin in microvascular damage associated with diabetes.
Why it matters
Potential benefit: If successful, this study could lead to new insights into the mechanisms of diabetic peripheral neuropathy and potential therapeutic targets.
How similar studies have gone: While the specific role of amylin in diabetic peripheral neuropathy is not extensively studied, related research on amylin's effects in diabetes has shown promising results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject has been diagnosed with Type-2 Diabetes. * Subject shows mild-to-severe peripheral neuropathy, as determined by Nerve Conduction Velocity (NCV) tests. Exclusion Criteria: * Subject has not been diagnosed with Type-2 Diabetes. * Subject shows average, or above average performance on Nerve Conduction Velocity (NCV) tests.
Where it's running
-
University of Kentucky - Kentucky Neuroscience Institute
Lexington, Kentucky, United States Recruiting -
UK Robert Straus Behavioral Science Laboratory
Lexington, Kentucky, United States Active not recruiting
Study contacts
- Principal investigator: John T Slevin, M.D., M.B.A. — University of Kentucky Department of Neurology
- Study coordinator: Rani Priyanka Vasireddy, MBBS, MHA
- Email: rvasireddy@uky.edu
- Phone: 859-218-5076
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cryoneurolysis for Chronic Pain: 6- and 12-Month Outcomes in Routine Care
This study tests whether cryoneurolysis, done as part of standard care for people with chronic pain, leads to meaningful improvements over 6 to 12 months.
-
Acupuncture and Exercise for EV-Pembro–Induced Peripheral Neuropathy
This study tests whether adding acupuncture to a gentle virtual exercise program helps reduce chemotherapy-induced nerve problems in bladder cancer patients taking EV and pembrolizumab.
-
Tai Chi, alpha-lipoic acid, and acupuncture to reduce chemotherapy-related peripheral neuropathy in people treated for gastrointestinal cancers.
This 16-week pilot will try virtual Tai Chi/Qi Gong or alpha-lipoic acid, adding acupuncture for those who don't improve, to see if these approaches reduce chemo-related nerve numbness and tingling in people treated for GI cancers.
-
Adaptive transcutaneous magnetic stimulation for posttraumatic peripheral neuropathic pain
This project will try adaptive transcutaneous magnetic stimulation (AtMS) to see if it reduces post-traumatic peripheral neuropathic pain in veterans and active-duty military.
-
Leia sensory prosthesis for balance and gait in people with peripheral neuropathy
A wearable, non-invasive device is tested to see if it helps adults with peripheral neuropathy walk more stably and balance better over a set period.
-
Desloratadine to see if it can prevent nerve damage from taxane chemotherapy in breast cancer
A randomized, placebo-controlled test to see if desloratadine can help prevent taxane-induced peripheral neuropathy in adults with breast cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.